Sodium glucose cotransporter-2 (SGLT2) inhibitors currently approved by the US Food and Drug Administration include empagliflozin (Jardiance), canagliflozin (Invokana), dapagliflozin (Farxiga), and ertugliflozin (Steglatro).

Recently, the world of nephrology rejoiced at another “positive” trial in nephrology: Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD) (1).

In 2020, acute kidney injury (AKI) came to the forefront during the COVID-19 pandemic as nephrologists struggled to understand the pathophysiology of COVID-19-associated AKI and to provide timely and effective nondialytic and dialytic care to the large volume of patients who overwhelmed healthcare facilities.

The year 2020 brought a pandemic that prompted the kidney community to modify daily clinical practice to avoid severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in our patients with advanced chronic kidney disease (CKD).

As a child, Kenar Jhaveri, MD, FASN, often found creative ways to demonstrate his school learning, from performing skits to creating crossword puzzles. That continued in his nephrology career teaching medical trainees. Now, Jhaveri is excited to bring his passion for innovation and education to ASN Kidney News, where he becomes the new editor-in-chief in January 2021.

Nearly 800,000 patients in the United States have end-stage kidney disease, with more than 550,000 receiving maintenance dialysis (1). Compared to the general population, dialysis patients incur a greater burden of illness, with more comorbid conditions, including diabetes mellitus, hypertension, intrinsic pulmonary disease, cardiovascular and cerebrovascular disease, obesity, and frailty.

#NoMoreManels, a hashtag that continues to trend on social media in 2021, both within and outside nephrology, is used to draw attention to panels of all-men speakers and moderators, despite an active US physician workforce that is over one-third women (1).